Education

Personal Finance How To Use TipRanks TipRanks Labs Webinar Center Glossary FAQs

About Us

About TipRanks Contact Us Careers Reviews Mobile APP

Working with TipRanks

Enterprise Solutions Top Online Brokers Become an Affiliate

News Trending Portfolio

TOOLS

Top Smart Score Stocks

STOCKS

Best High Yield Dividend Stocks

Dividend Aristocrats

Dividend Stock Comparison

New

Dividend Calculator

Dividend Returns Comparison

Dividend Calendar

Top Analysts

Top Financial Bloggers

Top-Performing Corporate Insiders

Top Hedge Fund Managers

Top Research Firms

Top Individual Investors

News

Portfolio

Personal Finance Center

Mortgages

Loans

Investing & Retirement

Spending & Savings

Calculators

Compound Interest Calculator

Student Loan Calculator

401k Retirement Calculator

Education

About Us

Working with TipRanks

Enterprise Solutions

Top Online Brokers

Become an Affiliate

Altamira Therapeutics (CYTO)

NASDAQ:CYTO

CYTO

Altamira Therapeutics

RESEARCH TOOLS

Top Smart Score Stocks

Stock Screener

reports

Holding CYTO?

Track your performance easily

Link Broker

Altamira Therapeutics (CYTO) Income Statement

598 Followers

Altamira Therapeutics Income Statement

Last quarter (Q ), Altamira Therapeutics's total revenue was CHF―, a decrease of ― from the same quarter last year. In Q, Altamira Therapeutics's net income was CHF―. See Altamira Therapeutics’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 23	Dec 22	Dec 21	Dec 20	Dec 19
Total Revenue	-	CHF 27.29K	CHF 305.62K	CHF 63.88K	CHF 0.00	CHF 0.00
Cost of Revenue	-	-	CHF 1.44M	CHF 2.24M	CHF 0.00	-
Gross Profit	-	CHF 27.29K	CHF -1.14M	CHF -2.18M	CHF 0.00	-
Operating Expense	-	CHF 6.17M	CHF 25.70M	CHF 14.81M	CHF 5.28M	CHF 7.26M
Operating Income	-	CHF -6.14M	CHF -26.84M	CHF -16.98M	CHF -5.28M	CHF -7.26M
Net Non Operating Interest Income Expense	-	CHF -1.31M	CHF -911.87K	CHF -189.69K	CHF -134.89K	CHF -10.75K
Other Income Expense	-	CHF -188.75K	CHF -1.66M	CHF -69.06K	CHF -2.80M	CHF 444.15K
Pretax Income	-	CHF -7.27M	CHF -26.04M	CHF -16.77M	CHF -8.22M	CHF -6.83M
Tax Provision	-	-	CHF -10.33K	CHF 21.62K	CHF -21.28K	CHF -193.84K
Earnings From Equity Interest Net Of Tax	-	CHF -39.56K	CHF 709.45K	CHF 264.98K	-	-
Net Income Common Stockholders	-	CHF -3.87M	CHF -26.03M	CHF -16.80M	CHF -8.20M	CHF -6.63M
Basic EPS	-	CHF -7.88	CHF -29.13	-	CHF -1.36	CHF -2.28
Diluted EPS	-	CHF -7.88	CHF -29.13	-	CHF -1.36	CHF -2.28
Basic Average Shares	-	CHF 491.26K	CHF 910.72K	CHF 13.25M	CHF 6.01M	CHF 2.91M
Diluted Average Shares	-	CHF 491.26K	CHF 893.48K	-	CHF 6.01M	CHF 2.91M
Dividend Per Share	-	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	CHF 13.87K	CHF 27.36K
Total Expenses	-	CHF 6.17M	CHF 27.15M	CHF 17.05M	CHF 5.28M	CHF 7.26M
Net Income From Continuing And Discontinued Operation	-	CHF -3.87M	CHF -26.03M	CHF -16.80M	CHF -8.20M	CHF -6.63M
Normalized Income	-	CHF -5.34M	-	-	CHF -5.40M	CHF -7.06M
Interest Expense	-	-	-	-	CHF 135.15K	CHF 28.63K
EBIT	-	CHF -5.60M	CHF -25.13M	CHF -16.58M	CHF -8.09M	CHF -6.80M
EBITDA	-	CHF -5.48M	CHF -25.01M	CHF -16.51M	CHF -8.07M	CHF -6.77M

Currency in CHF

Altamira Therapeutics Earnings and Revenue History

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing